BioSpace News Archive

Biotech Beach

JenaValve Raises $100 Million to Advance Trilogy TAVR Solution

JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement systems, announced that it has completed the initial closing of a $100 million Series C financing.

August 31, 2022
·
3 min read
Business

LANNETT ANNOUNCES SUBJECT DOSING COMPLETE FOR PIVOTAL CLINICAL TRIAL OF BIOSIMILAR INSULIN GLARGINE

Lannett Company, Inc. (NYSE: LCI) today announced that subject dosing has been completed in the pivotal clinical trial of biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies (HEC).

August 31, 2022
·
2 min read
Genetown

ImmunoGen Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm

ImmunoGen, Inc. provided an update on the pivotal Phase 2 CADENZA study of pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm.

August 31, 2022
·
7 min read
Kinarus Therapeutics Reports H1 2022 Financial Results and Provides Corporate Update

Kinarus Therapeutics Holding AG reported results for the six months ended June 30, 2022, and provided a corporate update.

August 31, 2022
·
5 min read
Spexis announces presentation of half-year 2022 financial results and participation at upcoming industry and investor events in September

Spexis AG, a clinical-stage biopharmaceutical company focused on rare diseases and oncology, announced that the Company will hold a live call and webcast to discuss its half-year 2022 financial results and provide a business update on September 6, 2022, 8am ET / 2pm CET.

August 31, 2022
·
2 min read
Business

Junshi Biosciences Announces 2022 Interim Financial Results and Provides Corporate Updates

Shanghai Junshi Biosciences Co., Ltd, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its 2022 interim financial results and provided corporate updates.

August 31, 2022
·
12 min read
TikoMed’s ILB® mobilizes and modulates key growth factors that trigger a cascade of neuroprotective mechanisms able to target all neuroinflammation-driven diseases including ALS

TikoMed announced the publication in Frontiers in Phamacology of peer-reviewed research supporting the unique broad spectrum mechanism of action of TikoMed’s ILB® neuroprotective drug platform.

August 31, 2022
·
2 min read
Business

ProKidney Appoints Glenn Schulman, PharmD, MPH, as Senior Vice President of Investor Relations

ProKidney Corp., a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, announced the appointment of Glenn Schulman, PharmD, MPH, as Senior Vice President of Investor Relations.

August 31, 2022
·
6 min read
Drug Development

Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome In predictive animal models, BMB-101 demonstrated significant reduction in both the number and intensity of epileptic seizures

Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), today announced that it has dosed the first patient in a Phase I trial (NCT 05397041) for its lead product, BMB-101, for the treatment of Dravet Syndrome and other medical indications.

August 31, 2022
·
6 min read
Biotech Bay

The First Diagnostic Test for Long COVID Will Formally Launch in Europe in September 2022

The first diagnostic designed to identify patients with long COVID has received CE-IVD marking in Europe.

August 31, 2022
·
4 min read